Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Will The Male Hypogonadism Market Valuation Change Between Now And 2029?

In recent times, there has been a substantial increase in the size of the male hypogonadism market. It is expected to expand from a value of $3.75 billion in 2024 to $3.95 billion in 2025, displaying a compound annual growth rate (CAGR) of 5.3%. The historical growth can be linked to a variety of factors such as an aging population, increased awareness and diagnosis, lifestyle influences, chronic diseases, and people’s behavior in seeking treatment.

It’s anticipated that the male hypogonadism market will experience significant growth in the upcoming years, with projections reaching “$4.99 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. This growth during the forecasted timeframe can be linked to increased awareness, the prevalence of lifestyle-related diseases, innovative treatment approaches, a focus on men’s health, plus accessibility to telemedicine and healthcare. Key trends of the forecast period encompass a concentration on psychological and sexual health, the investigation into nutraceuticals and lifestyle changes, market development in emerging economies, cooperative research efforts, and a focus on long-term safety and surveillance.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9969&type=smp

What External And Internal Drivers Are Influencing The Male Hypogonadism Market?

The rising levels of infertility are predicted to fuel the expansion of the male hypogonadism market. Infertility, defined as the inability to conceive after a year or more of regular unprotected intercourse, can impact both male and female reproductive systems. Male hypogonadism can potentially cause reduced sperm production and infertility, thus leading to an escalation in male infertility rates. Consequently, the augmented rates of male infertility are anticipated to spur the growth of the male hypogonadism market. For example, the Office for National Statistics, a government department based in the UK, reported in February 2024 that the total fertility rate (TFR) rose to 1.49 children per woman in 2022 from 1.55 in 2021. Therefore, the augmentation in infertility rates is propelling the growth of the male hypogonadism market.

What Are The Primary Segmentation Parameters In The Male Hypogonadism Market?

The male hypogonadism market covered in this report is segmented –

1) By Type: Klinefelters Syndrome, Kallmann Syndrome, Pituitary Disorders, Other Types

2) By Drug Delivery: Topical Gels, Injectables, Transdermal Patches, Other Drug Deliveries

3) By Therapy: Testosterone Therapy, Gonadotropin-Releasing Hormone Therapy

Subsegments:

1) By Klinefelter’s Syndrome: 47,XXY Syndrome, Other Variants

2) By Kallmann Syndrome: Isolated Kallmann Syndrome, Syndromic Kallmann Syndrome

3) By Pituitary Disorders: Hypopituitarism, Pituitary Tumors, Other Pituitary Disorders

4) By Other Types: Androgen Insensitivity Syndrome, Testicular Dysgenesis Syndrome, Genetic Mutations And Disorders

Which Emerging Trends Are Reshaping The Male Hypogonadism Market Landscape?

The development of novel products is becoming an increasingly significant trend within the male hypogonadism market. Businesses within this market space are engaging in product innovation to maintain their standing. As an example, Halozyme, an American biotech firm, in June 2022, introduced Tlando – an oral solution for testosterone replacement therapy in male hypogonadism. This prescribed medication that encompasses testosterone is FDA-approved as the first oral testosterone treatment. It is utilized for treating adult males who suffer from low or zero testosterone levels due to certain health conditions.

Which Organizations Are At The Forefront Of The Male Hypogonadism Market?

Major companies operating in the male hypogonadism market include Pfizer Inc., Bayer AG, Eli Lilly and Company Ltd., Endo International plc., Merck & Co. Inc., Ferring Pharmaceuticals, Finox Biotech AG, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Perrigo Company plc, IBSA Institut Biochimique SA, Sun Pharmaceutical Industries Limited, Glenmark Pharmaceuticals Limited, Antares Pharma Inc., Zydus Cadila LLC, Besins Healthcare Ltd., Clarus Therapeutics Holdings Inc., Foresee Pharmaceuticals Co. Ltd., Lipocine Inc., Myovant Sciences Ltd., Sandoz International GmbH, Shionogi & Co. Ltd., TherapeuticsMD Inc., Viking Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/male-hypogonadism-global-market-report

Which Region Holds The Greatest Opportunity For Male Hypogonadism Market Expansion?

North America was the largest region in the male hypogonadism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the male hypogonadism market report during the forecast period. The regions covered in the male hypogonadism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=9969&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model